NCT06205524View on ClinicalTrials.gov

A Study to Evealuate Safety and Immunogenicity of TI-0010 SARS-CoV-2 Vaccine in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

February 1, 2025

Conditions
COVID-19COVID-19 Immunisation
Interventions
BIOLOGICAL

TI-0010

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (1)

233002

RECRUITING

The Second Affiliated Hospital Of BengBu Medical College, Bengbu

Sponsors

Collaborators (1)

Therorna
All Listed Sponsors
collaborator

Therorna

INDUSTRY

lead

National Drug Clinical Trial Institute of the Second Affiliated Hospital of Bengbu Medical College

OTHER

NCT06205524 - A Study to Evealuate Safety and Immunogenicity of TI-0010 SARS-CoV-2 Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter